1	Tryptophan and arginine metabolism is significantly altered at the time of admission in
2	hospital for severe COVID-19 patients: findings from longitudinal targeted metabolomics
3	analysis
4	Running title: Metabolomic profiling in severe COVID-19 patients.
5	Laura Ansone <sup>*a</sup> & Monta Ustinova <sup>*a</sup> , Anna Terentjeva <sup>b</sup> , Ingus Perkons <sup>c</sup> , Liga Birzniece <sup>a</sup> ,
6	Vita Rovite <sup>a</sup> , Baiba Rozentale <sup>b</sup> , Ludmila Viksna <sup>b</sup> , Oksana Kolesova <sup>b</sup> , Kristaps Klavins <sup>d</sup> ,
7	Janis Klovins <sup>a#</sup> .
8	<sup>a</sup> Latvian Biomedical Research and Study Centre, Ratsupites iela 1, Riga, Latvia, LV-1067.
9	<sup>b</sup> Riga Stradins University, Dzirciema iela 16, Riga, Latvia, LV-1007.
10	<sup>c</sup> Institute of Food Safety, Animal Health and Environment (BIOR), Lejupes iela 3, Riga, Latvia,
11	LV-1076.
12	<sup>d</sup> Riga Technical University, Kalku iela 1, Riga, Latvia, LV-1658.
13	*Laura Ansone and Monta Ustinova share the co-first authorship.
14	LA contributed in the sample analysis, patient recruitment process and sample collection, data
15	analysis and interpretation, drafting the manuscript.
16	MU contributed in patient recruitment process and sample collection, data analysis and
17	interpretation, funding acquisition, drafting the manuscript.
18	#Corresponding author: Klovins@biomed.lu.lv
19	Word count for the abstract: 160
20	Word count for the main text: 1133
21	
22	

### 23 Abstract

The heterogeneity in severity and outcome of COVID-19 cases points out the urgent need 24 for early molecular characterization of patients followed by risk-stratified care. The main 25 26 objective of this study was to evaluate the fluctuations of serum metabolomic profiles of COVID-19 patients with severe illness during the different disease stages in a longitudinal 27 manner. We demonstrate a distinct metabolomic signature in serum samples of 32 hospitalized 28 29 patients at the acute phase compared to the recovery period, suggesting the tryptophan (tryptophan, kynurenine, and 3-hydroxy-DL-kynurenine) and arginine (citrulline and ornithine) 30 metabolism as contributing pathways in the immune response to SARS-CoV-2 with a potential 31 link to the clinical severity of the disease. In addition, we provide evidence for glutamine 32 metabolism in M2 macrophages as a complementary process and contribution of phenylalanine 33 and tyrosine in the molecular mechanisms underlying the severe course of the infection. In 34 35 conclusion, our results provide several functional metabolic markers for disease progression and severe outcome with potential clinical application. 36

### 37 **Importance**

Although the host defense mechanisms against SARS-CoV-2 infection are still poorly described, they are of central importance in shaping the course of the disease and the possible outcome. Metabolomic profiling may complement the lacking knowledge of the molecular mechanisms underlying clinical manifestations and pathogenesis of COVID-19. Moreover, early identification of metabolomics based biomarker signatures is proved to serve as an effective approach for the prediction of disease outcome. Here we provide the list of metabolites describing the severe, acute phase of the infection and bring the evidence of crucial metabolic

pathways linked to aggressive immune responses. Finally, we suggest metabolomic phenotyping
as a promising method for developing personalized care strategies in COVID-19 patients.

47 Main text

More than a year has passed since the World Health Organization (WHO) announced the COVID-19 outbreak as a pandemic in March 2020, following the rapid spread of the SARS-CoV-2 virus (1). The clinical course of COVID-19 is versatile, the infection of the SARS-CoV-2 virus not only varies in its severity from asymptomatic or mild and moderate respiratory disease (80%) to clinically severe or critical life-threatening disease (20%) but also varies in a range of organs the disease can affect (2, 3). Diverse clinical trajectories seem to be the result of the immune response differences between individuals (4).

55 Multiple innate and adaptive immune system pathways that produce inflammatory 56 molecules against the virus and virus-infected human cells are triggered after the SARS-CoV-2 57 entry in the cell, with characteristic overexpression of proinflammatory cytokines (e.g. IL-6, 58 TNF $\alpha$ , IFN- $\gamma$ ) known as cytokine storm in the most severe cases (4–6). The host's immune 59 responses typically involve changes in metabolic processes at the cellular level, reflecting the 50 host-defense mediators and underlying mechanisms (7).

Detailed understanding of the molecular mechanisms behind COVID-19 pathogenesis and inflammatory response is needed to predict and reduce individual risks, develop therapeutic strategies, and reduce the overall ~2% mortality rate (mortality in hospitalized patients can be up to 30%) (8, 9). The human blood sera metabolome (defined as small molecules <1500–2000 Da) reflects the organism's metabolic state and is widely used to gain a deeper understanding of the pathogenesis of diseases. Recent reports of metabolomics studies highlight the pivotal role of cellular metabolites in programming immune response to SARS-CoV-2 infection (10–13).

Considering the extremely high heterogeneity of the COVID-19 disease and lack of promising predictive biomarkers, we believe that implications of longitudinal metabolite profiling may be beneficial in understanding the underlying mechanisms of the diverse course of the disease and promote the early identification of people at increased risk of severe illness from COVID-19 and related complications.

We performed quantitative targeted metabolome analysis with liquid chromatographymass spectrometry (LC-MS) in blood sera of 32 hospitalized COVID-19 patients at the acute phase (time of admission at the hospital) and the recovery phase ( $40 \pm 14.92$  days) of the disease (see Text S1 in the supplemental material for a detailed description of methods). Written informed consent was obtained from every participant before their inclusion in the study, and the study protocol was approved by the Central Medical Ethics Committee of Latvia (No. 01-29.1.2/928).

As expected, the clinical blood tests revealed abnormal hematological parameters for the 80 majority of study participants at the time of hospitalization, with a high variation in platelet 81 82  $(202.94 \pm 65.26 \,\mu\text{L})$  levels and low lymphocyte measurements  $(0.64 \pm 0.56 \,\mu\text{L})$ , which coincides with previously reported lymphopenia as the hallmark of severe COVID-19 cases. We also 83 observed a high variation of several markers (e.g. alanine aminotransferase, bilirubin, lactate C-84 85 reactive protein) indicating renal and hepatic dysfunction, myocarditis, inflammation, and coagulation, which confirms the systemic response to the infection in our study cohort(2, 14)86 87 (see Table S1 in the supplemental material).

Out of 51 metabolites analyzed by LC-MS, 22 metabolites showed significantly altered levels (paired t-test, FDR<0.05) in the serum samples during the acute phase in comparison to the recovery phase (Table 1), where concentrations for 16 compounds were significantly

elevated, whereas 8 metabolites were decreased. The hierarchical clustering and principal
component analysis of the obtained metabolomic profiles showed clear metabolomics-based
discrimination of samples collected in different phases of the disease (Figure1. A and B),
indicating an altered metabolic activity during infection. Pathway analysis revealed 13
significantly enriched pathways (FDR<0.05), including phenylalanine, tyrosine and tryptophan</li>
biosynthesis, D-glutamine and D-glutamate metabolism and arginine biosynthesis (Figure1 C,
Table S3). Statistical analysis was done with Metaboanalyst version 5.0 (15).

We found L-glutamine (Figure 1D) as the most significantly changed amino acid between the paired samples with reduced acute phase concentrations. It is known that glutamine deprivation and decreased glutaminolysis inhibits M2 macrophage polarization, which may partly explain the hyperinflammatory state in severe COVID-19 cases (16, 17). Moreover, the beneficial effect of glutamine has been proposed in multiple studies, where adding enteral Lglutamine to the regular nutrition shortened the duration of hospitalization and improved the outcome in moderate to severe COVID-19 cases (18, 19).

105 Two other amino acids involved in arginine catabolism through the Urea cycle: citrulline (Figure 1D) and ornithine (Table 1) were found to significantly change between the acute and 106 107 recovery phases. However, alterations in the levels of L-arginine itself were not detected. Low blood plasma citrulline levels have already been reported in COVID-19 patients, whereas in 108 patients with severe sepsis, the decreased citrulline levels are associated with acute respiratory 109 110 distress syndrome (11, 13, 20). Since arginine can be metabolized to creatine and then to 111 creatinine, both varying highly in our study cohort according to regular blood tests performed during hospitalization, arginine catabolism may be implicated in disturbed kidney function of 112 113 COVID-19 patients (21).

114 Three out of 22 metabolites showing significantly changed levels between acute infection 115 and recovery phase are involved in the tryptophan-kynurenine pathway: L-tryptophan, 116 kynurenine, and 3-hydroxy-DL-kynurenine (Figure 1D, Table 1). The reduction of tryptophan 117 levels and increase of kynurenine, 3-hydroxy-DL-kynurenine in the acute phase supports the conclusions of previous reports and confirms this pathway's key role in severe COVID-19 cases 118 (10, 11). In vitro experiments have shown that tryptophan deprivation sensitizes T cells to 119 120 apoptosis, inhibits proliferation of T cells, and plays a role in CD8 T-cell suppression in cancer (22, 23). Notably, the tryptophan-kynurenine pathway shows a modulatory effect on the 121 macrophage-mediated responses by targeting the synthesis of the metabolic coenzyme 122 NAD+(24, 25). According to Thomas et al. dysregulated tryptophan metabolism, an essential 123 regulator of inflammation and immunity may be a potential explanation for severity in older 124 125 COVID-19 patients (Thomas et al., 2020).

Finally, we observed a significant difference in L-phenylalanine (Figure 1D) and tyrosine 126 levels in our cohort between the analyzed disease phases, both already suggested as metabolic 127 128 hot spots of COVID-19 before (26). In sepsis and HIV-1 infection, the increased phenylalanine sera concentrations are linked to immune activation and increased cardiovascular event risk (27-129 29). Although the mechanisms behind this association are not well studied, it is in line with 130 microvascular endothelial damage and higher coagulation risk characteristic to both: coronary 131 heart disease and severe COVID-19 (29). Phenylalanine and tyrosine are catabolized to 132 dopamine and epinephrine, and the latter has been employed in cardiac arrest as a result of 133 134 cytokine storm, characteristic to severe COVID-19 patients(30).

In conclusion, our study shows that metabolomic profiling provides novel insights into thepathogenesis of host-defense mechanisms and may be further applied for rapid biomarker

137	discovery in infectious disease. These discoveries could show novel therapeutic strategies as
138	indirect targets to fasten the recovery process after severe COVID-19. To the best of our
139	knowledge, this is the first longitudinal study covering metabolomic profiling of severe COVID-
140	19 patients.
141	Data availability
142	The raw data supporting the current study are available from the corresponding author on
143	request.
144	Acknowledgments
145	This study is funded by the Ministry of Education and Science, Republic of Latvia, project
146	"Establishment of COVID-19 related biobank and integrated platform for research data in
147	Latvia", project No. VPP-COVID-2020/1-0016.
148	We acknowledge The Boris and Inara Teterev Foundation for support to Riga Stradins
149	University in patient sample collection.
150	The authors acknowledge the Latvian Biomedical Research and Study Centre and the Genome
151	Database of the Latvian Population for providing the infrastructure, biological material, and data.
152	Author contributions
153	LA, KK, IP, LB performed the sample analysis; MU, VR, LA, BR, LV, OK were involved in
154	patient recruitment process and sample collection; AT ensured the clinical data acquisition; MU,
155	LA drafted the manuscript; JK provided critical revision of the manuscript; LA, KK, MU
156	performed the data analysis and interpretation; MU, JK collaborated in funding acquisition, JK

- 157 performed supervision and conceptualization of the study. All authors read and approved the
- 158 final manuscript.

#### 159 **Declaration of Interests**

160 The authors declare no competing interests.

#### 161 **References**

- World Health Organization. 2020. Coronavirus disease 2019 (COVID-19) Situation
   Report 51.
- 164 2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei
- 165 Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. 2020. Clinical course and risk
- factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective
  cohort study. Lancet 395:1054–1062.
- 168 3. Wu Z, McGoogan JM. 2020. Characteristics of and Important Lessons from the
- 169 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of
- 17072314 Cases from the Chinese Center for Disease Control and Prevention. JAMA J Am
- 171 Med Assoc 323:1239–1242.
- 4. García LF. 2020. Immune Response, Inflammation, and the Clinical Spectrum of 11:4–8.
- 173 5. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian
- DS. 2020. Dysregulation of immune response in patients with coronavirus 2019 (COVIDin Wuhan, China. Clin Infect Dis 71:762–768.
- 176 6. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. 2020. COVID-
- 177 19: consider cytokine storm syndromes and immunosuppression. Lancet 395:1033–1034.

178	7.	Pearce EL, Pearce EJ. 2013. Metabolic Pathways in Immune Cell Activation and
179		Quiescence. Immunity 38:633–643.

Asch DA, Sheils NE, Islam N, Chen Y, Werner RM, Buresh J, Doshi JA. 2020. Variation
 in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6

- 182 Months of the Pandemic 19104:1–8.
- 183 9. Bellan M, Patti G, Hayden E, Azzolina D, Pirisi M, Acquaviva A, Aimaretti G, Valletti
- 184 PA, Angilletta R, Arioli R, Avanzi GC, Avino G, Balbo PE, Baldon G, Baorda F, Barbero
- 185 E, Baricich A, Barini M, Adesi FB, Battistini S, Beltrame M, Bertoli M, Bertolin S,
- 186 Bertolotti M, Betti M, Bobbio F, Boffano P, Boglione L, Borrè S, Brucoli M, Calzaducca
- 187 E, Cammarata E, Cantaluppi V, Cantello R, Capponi A, Carriero A, Casciaro FG, Castello
- 188 LM, Ceruti F, Chichino G, Chirico E, Cisari C, Cittone MG, Colombo C, Comi C, Croce
- 189 E, Daffara T, Danna P, Corte F Della, Vecchi S De, Dianzani U, Benedetto D Di, Esposto
- 190 E, Faggiano F, Falaschi Z, Ferrante D, Ferrero A, Gagliardi I, Gaidano G, Galbiati A,
- 191 Gallo S, Garavelli PL, Gardino CA, Garzaro M, Gastaldello ML, Gavelli F, Gennari A,
- 192 Giacomini GM, Giacone I, Via VG, Giolitti F, Gironi LC, Gramaglia C, Grisafi L, Inserra
- 193 I, Invernizzi M, Krengli M, Labella E, Landi IC, Landi R, Leone I, Lio V, Lorenzini L,
- 194 Marzari L, Marzullo P, Mennuni M, Montabone C. 2020. Fatality rate and predictors of
- 195 mortality in an Italian cohort of hospitalized COVID  $\Box$  19 patients. Sci Rep 1–10.
- 196 10. Blasco H, Bessy C, Plantier L, Lefevre A, Piver E, Bernard L, Marlet J, Stefic K, Benz-de
- 197 Bretagne I, Cannet P, Lumbu H, Morel T, Boulard P, Andres CR, Vourc'h P, Hérault O,
- 198 Guillon A, Emond P. 2020. The specific metabolome profiling of patients infected by
- 199 SARS-COV-2 supports the key role of tryptophan-nicotinamide pathway and cytosine
- 200 metabolism. Sci Rep 10:1–12.

201	11.	Thomas T, Stefanoni D, Reisz JA, Nemkov T, Bertolone L, Francis RO, Hudson KE,
202		Zimring JC, Hansen KC, Hod EA, Spitalnik SL, D'Alessandro A. 2020. COVID-19
203		infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and
204		renal status. JCI Insight 5.
205	12.	Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, Quan S, Zhang F, Sun R, Qian L, Ge W, Liu
206		W, Liang S, Chen H, Zhang Y, Li J, Xu J, He Z, Chen B, Wang J, Yan H, Zheng Y, Wang
207		D, Zhu J, Kong Z, Kang Z, Liang X, Ding X, Ruan G, Xiang N, Cai X, Gao H, Li L, Li S,
208		Xiao Q, Lu T, Zhu YJ, Liu H, Chen H, Guo T. 2020. Proteomic and Metabolomic
209		Characterization of COVID-19 Patient Sera. SSRN Electron J
210		https://doi.org/10.1101/2020.04.07.20054585.
211	13.	Lawler NG, Gray N, Kimhofer T, Boughton B, Gay M, Yang R, Morillon A-C, Chin S-T,
212		Ryan M, Begum S, Bong SH, Coudert JD, Edgar D, Raby E, Pettersson S, Richards T,
213		Holmes E, Whiley L, Nicholson JK. 2021. Systemic Perturbations in Amine and
214		Kynurenine Metabolism Associated with Acute SARS-CoV-2 Infection and Inflammatory
215		Cytokine Responses. J Proteome Res https://doi.org/10.1021/acs.jproteome.1c00052.
216	14.	Henry BM, Helena M, Oliveira S De, Benoit S. 2020. Hematologic , biochemical and
217		immune biomarker abnormalities associated with severe illness and mortality in
218		coronavirus disease 2019 ( COVID-19 ): a meta-analysis 58:1021–1028.
219	15.	Xia J, Wishart DS. 2011. Web-based inference of biological patterns, functions and
220		pathways from metabolomic data using MetaboAnalyst. Nat Protoc 6:743–760.
221	16.	Liu P-S, Wang H, Li X, Chao T, Teav T, Christen S, Di Conza G, Cheng W-C, Chou C-H,
222		Vavakova M, Muret C, Debackere K, Mazzone M, Huang H-D, Fendt S-M, Ivanisevic J,

- Ho P-C. 2017. α-ketoglutarate orchestrates macrophage activation through metabolic and
  epigenetic reprogramming. Nat Immunol 18:985–994.
- 17. Martinez FO, Combes TW, Orsenigo F, Gordon S. 2020. Monocyte activation in systemic
- 226 Covid-19 infection: Assay and rationale. EBioMedicine 59:102964.
- 18. Cengiz M, Uysal BB, Ikitimur H, Ozcan E, Aktepe E, Yavuzer H, Yavuzer S. 2020. Effect
- of oral L -Glutamine supplementation on Covid-19 treatment 33:24–31.
- 19. Obayan AOE. 2021. Infectious Diseases and Epidemiology Overview of the Rationale for
- 230 L-Glutamine Treatment in Moderate-Severe COVID-19 Infection Proposed Flowchart of
- In fl ammatory Response In COVID-19 Infec  $\Box$  on 7:1–7.
- 232 20. Ware LB, Magarik JA, Wickersham N, Cunningham G, Rice TW, Christman BW,

Wheeler AP, Bernard GR, Summar ML. 2013. Low plasma citrulline levels are associated with acute respiratory distress syndrome in patients with severe sepsis 1–8.

235 21. Reyes AA, Karl IE, Klahr S. 1994. Role of arginine in health and in renal disease. Am J
236 Physiol Physiol 267:F331–F346.

237 22. Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL. 2002. Tryptophan
238 deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology
239 107:452–460.

- 240 23. Greene LI, Bruno TC, Christenson JL, D' Alessandro A, Culp-Hill R, Torkko K,
- 241 Borges VF, Slansky JE, Richer JK. 2019. A Role for Tryptophan-2,3-dioxygenase in CD8
- 242 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient

243 Plasma. Mol Cancer Res 17:131 LP – 139.

2 + 2 + 2 + 1 minut i b, Liu L, moon i i k, jobin i b, boyo C, minut b, contropolo k, minut $O$ ,	O. Lee	Wang	pois K.	. Contre	Mhatre S.	Dove C.	Joshi AU	, Moon PK,	S. Liu L.	Minhas PS	24.	244
---	--------	------	---------	----------	-----------	---------	----------	------------	-----------	-----------	-----	-----

- 245 BA, Coronado M, Bernstein D, Snyder MP, Migaud M, Majeti R, Mochly-Rosen D,
- Rabinowitz JD, Andreasson KI. 2019. Macrophage de novo NAD+ synthesis specifies

immune function in aging and inflammation. Nat Immunol 20:50–63.

- 248 25. Van Gool F, Gallí M, Gueydan C, Kruys V, Prevot P-P, Bedalov A, Mostoslavsky R, Alt
- FW, De Smedt T, Leo O. 2009. Intracellular NAD levels regulate tumor necrosis factor
- 250 protein synthesis in a sirtuin-dependent manner. Nat Med 15:206–210.
- 251 26. Pang Z, Zhou G, Chong J, Xia J. 2021. Comprehensive meta-analysis of covid-19 global
  252 metabolomics datasets. Metabolites 11:1–14.
- 253 27. Zangerle R, Kurz K, Neurauter G, Kitchen M, Sarcletti M, Fuchs D. 2010. Increased
- blood phenylalanine to tyrosine ratio in HIV-1 infection and correction following effective
  antiretroviral therapy. Brain Behav Immun 24:403–408.
- 256 28. Ploder M, Neurauter G, Spittler A, Schroecksnadel K, Roth E, Fuchs D. 2008. Serum
  257 phenylalanine in patients post trauma and with sepsis correlate to neopterin
  258 concentrations. Amino Acids 35:303–307.
- 259 29. Würtz P, Havulinna AS, Soininen P, Tynkkynen T, Prieto-Merino D, Tillin T, Ghorbani

A, Artati A, Wang Q, Tiainen M, Kangas AJ, Kettunen J, Kaikkonen J, Mikkilä V, Jula A,

- 261 Kähönen M, Lehtimäki T, Lawlor DA, Gaunt TR, Hughes AD, Sattar N, Illig T, Adamski
- J, Wang TJ, Perola M, Ripatti S, Vasan RS, Raitakari OT, Gerszten RE, Casas J-P,
- 263 Chaturvedi N, Ala-Korpela M, Salomaa V. 2015. Metabolite profiling and cardiovascular
- event risk: a prospective study of 3 population-based cohorts. Circulation2015/01/08.
- 265 131:774–785.

30. Luo P, Liu D, Li J. 2021. Epinephrine use in COVID-19: friend or foe? Eur J Hosp Pharm
267 28:e1 LP-e1.

268

269 Figures

Figure 1. Targeted metabolomic analysis of longitudinal serum samples of hospitalized 270 COVID-19 patients. (A) Heatmap and hierarchical clustering of top 22 significantly altered 271 metabolites. Each column represents one sample: (0, green) - samples collected in the acute 272 273 phase, (1, red) - samples collected during the recovery phase, each row conforms to a specific 274 metabolite expressed in normalized, log transformed concentration value. (B) Principal 275 component analysis showing clear discrimination of samples collected in the acute and recovery 276 phases of infection based on the obtained metabolite profiles. (C) Scatter plot representing the most relevant metabolic pathways from KEGG library arranged by adjusted p-values (obtained 277 by Global Test pathway enrichment analysis) on Y-axis, and pathway impact values (from 278 279 pathway topology analysis) on X-axis. The node color is based on its p-value and the node radius is determined based on their pathway impact values. (D) Boxplots showing the normalized levels 280 of the most functionally relevant metabolites during the acute phase (0) and the recovery phase 281 (1) of the infection, described as the minimum value, the first quartile, the median, the third 282 quartile, and the maximum value with the black dots representing each sample. 283

284

285

286

2	8	7
---	---	---

288

# 289 Tables

- Table 1. Serum metabolites showing significantly altered levels comparing measures obtained
- 291 during the acute phase and recovery phase of the disease.

Compound	Fold change	False discovery rate
L-Glutamine	0.72	5.71E-08
Citrulline	0.48	9.16E-08
3-Hydroxy-DL-Kynurenine	10.51	6.79E-07
L-Phenylalanine	1.33	6.79E-07
L-Methionine	1.47	1.62E-06
Isovalerylcarnitine	2.01	1.78E-06
4-Hydroxyproline	0.42	1.99E-06
Kynurenine	1.71	2.67E-06
L-Asparagine	1.51	3.88E-05
L-Glutamic acid	1.65	4.61E-05
L-Valine	1.26	7.73E-05
Carnitine	1.25	8.90E-05
L-Tryptophan	0.83	2.87E-04
L-Tyrosine	1.14	2.87E-04
L-Threonine	1.45	2.15E-03
L-Proline	0.86	3.23E-03
Taurine	1.36	6.01E-03

Ornithine	1.37	9.45E-03
L-Lysine	1.08	1.15E-02
L-Isoleucine	1.21	1.25E-02
L-Acetylcarnitine	1.21	2.34E-02
L-Octanoylcarnitine	0.75	3.85E-02

292

# 293 Appendixes

- 294 Text S1. Detailed Methods Description.
- Table S1. Characteristics of the study participants.
- 296 Table S2. Data matrix with quantified metabolite concentrations for targeted compounds,
- 297 determined by ultra-performance liquid chromatography-mass spectrometry.
- 298 Table S3. Significant pathways based on enrichment procedures.

